Picture of Inhibikase Therapeutics logo

IKT Inhibikase Therapeutics Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapSucker Stock

Momentum

Relative Strength (%)
1m-10.69%
3m+5.25%
6m-48.19%
1yr+4.88%
Volume Change (%)
10d/3m-43.7%
Price vs... (%)
52w High-67.02%
50d MA-3.49%
200d MA-26.72%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-371.05%
Return on Equity-149.69%
Operating Margin-23885.07%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202431st Dec 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of Inhibikase Therapeutics EPS forecast chart

Profile Summary

Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing therapeutics for Parkinson’s disease and related disorders. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its lead program risvodetinib (also known as IkT-148009), an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson’s disease inside and outside the brain as well as other diseases that arise from Ableson Tyrosine Kinases. Its multi-therapeutic pipeline is pursuing Parkinson’s-related disorders of the brain and GI tract, orphan indications related to Parkinson’s disease such as Multiple System Atrophy, and drug delivery technologies for kinase inhibitors such as IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate. The Company’s RAMP medicinal chemistry program has identified a number of follow-on compounds to IkT-148009 to be potentially applied to other cognitive and motor function diseases of the brain.

Directors

    Last Annual
    December 31st, 2023
    Last Interim
    June 30th, 2024
    Incorporated
    June 3rd, 2010
    Public Since
    December 23rd, 2020
    No. of Shareholders
    14
    No. of Employees
    8
    Sector
    Biotechnology & Medical Research
    Industry
    Healthcare
    Exchange
    us flag iconNASDAQ Capital Market
    Shares in Issue
    7,464,070

    IKT Share Price Performance

    Upcoming Events for IKT

    Q3 2024 Inhibikase Therapeutics Inc Earnings Release

    Q4 2024 Inhibikase Therapeutics Inc Earnings Release

    Similar to IKT

    Picture of 180 Life Sciences logo

    180 Life Sciences

    us flag iconNASDAQ Capital Market

    Picture of Abeona Therapeutics logo

    Abeona Therapeutics

    us flag iconNASDAQ Capital Market

    Picture of ABVC Biopharma logo

    ABVC Biopharma

    us flag iconNASDAQ Capital Market

    Picture of Acesis Holdings logo

    Acesis Holdings

    us flag iconNASDAQ Capital Market

    Picture of Achieve Life Sciences logo

    Achieve Life Sciences

    us flag iconNASDAQ Capital Market

    FAQ